#Israel #CollPlant #rhCollagen #Rehovot #LightSolver

CollPlant Biotechnologies Reports Q2 2026 Financial Results

CollPlant Biotechnologies (Nasdaq: CLGN), based in Rehovot, Israel, has released its financial standings for the second quarter of 2026, alongside notable corporate developments. The spotlight is on their acquisition of LightSolver, a move that marks a significant step into the high-performance computing (HPC) and photonics computing sectors.

Strategic Acquisition of LightSolver

The acquisition of LightSolver has been strategically positioned to expand CollPlant's technological portfolio and boost its market presence. Yehiel Tal, the CEO of CollPlant, emphasized that LightSolver’s innovative Laser Processing Unit (LPU) could potentially enhance HPC workloads by a monumental factor, with prior research suggesting accelerations of up to 80,000 times compared to traditional GPU algorithms. Dr. Ruti Ben Shlomi, co-founder of LightSolver, is now part of CollPlant's Board of Directors, which Tal believes brings invaluable scientific expertise as the company heads towards the commercialization of this cutting-edge technology.

Continued Commitment to Regenerative Medicine

Despite this notable diversion into computing technology, CollPlant continues to prioritize its leadership in regenerative medicine. The company's plant-derived recombinant human collagen (rhCollagen) platform is advancing, aimed at pivotal applications like 3D bioprinting of tissues and organs as well as in the field of medical aesthetics. CollPlant is focusing on establishing strategic partnerships with globally recognized entities to further its mission.

Financial Overview

The financial results for Q2 2026 reveal a total revenue of $108,000, a drop from $179,000 in Q2 2025, primarily attributed to decreased sales of rhCollagen-based products. For the first half of 2026, revenues totaled $181,000, significantly down from $2.2 million during the same period in 2025. This stark comparative plunge was largely due to a substantial development milestone payment of $2.0 million recognized in the prior year.

Cost-related expenses also reflected challenges the company faced, with a rise to $564,000 in gross costs for Q2 2026 from $186,000 a year prior. This increase was significantly driven by lower utilization of production capabilities and necessary inventory write-downs. As a result, CollPlant reported a gross loss of $456,000 for Q2 2026, contrasting sharply with a mere $7,000 loss in the same quarter of 2025.

Operating expenses decreased due to an intentional cost-reduction strategy, revealing $2.2 million for Q2 2026, down from $3.2 million the previous year. This included reductions in personnel-related costs and general operational expenses.

In terms of net loss, CollPlant experienced a $2.7 million decline this quarter, representing a basic loss per share of $1.89. Comparatively, they had reported a $3.3 million loss with a greater loss per share of $2.83 in Q2 2025.

Future Perspectives

CollPlant's focus moving forward entails a dual approach - cultivating its unique biotechnological applications while delving into the promising fields of high-performance computing. The acquisition of LightSolver is set to catalyze further innovations within the company and the industry, enhancing both technological capabilities and shareholder value in the long run.

For investors and stakeholders, these updates are pivotal, showcasing CollPlant’s dedication to strategic growth and diversification amidst fluctuating market conditions. The company's proactive adjustments and advancements affirm its potential resilience and future success. For further information, visit CollPlant's official website.